(2R,3S,4S,5R)-2,3,4,6-Tetrakis(benzyloxy)-5-hydroxyhexanal, 97%, 5g

Methyl 5-bromo-2-hydroxy-4-(trifluoromethyl)benzoate, 95.0%, 250mg

Objetivo de contraste de fase Plan PLPH 20x/0,40

TERT-BUTYL 6-AMINO-3,4-DIHYDROQUINOLINE-1(2H)-CARBOXYLATE, 95.0%, 1g

6-Nitroquinolin-2(1H)-one, 95.0%, 10g

2-Bromo-1-(4-fluorophenyl)propan-1-one, 95.0%, 5g

2-Bromo-5-chlorothiazole, 95.0%, 10g

4-Bromo-2,6-difluorobenzoic acid, 98.0%, 5g

3,6,9,12,15-PENTAOXAHEPTADECANEDIOIC ACID, 95%, 100mg

Triptycene-9,10-dicarboxaldehyde>96.0%(GC)1g

(E)-ETHYL 3-(THIAZOL-4-YL)ACRYLATE, 95.0%, 2g

Arachidonic acid, >99%, 5g

N1-(3-AMINOPROPYL)PENTANE-1,5-DIAMINE 3HCL, 95.0%, 1g